{"links":{"feed":"https://www.erudio.com/reports/optitrop-lung04-nct05870319/feed.json","html":"https://www.erudio.com/reports/optitrop-lung04-nct05870319","json":"https://www.erudio.com/reports/optitrop-lung04-nct05870319.json","markdown":"https://www.erudio.com/reports/optitrop-lung04-nct05870319.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"optitrop-lung04-nct05870319"}},"request":"https://www.erudio.com/contact?report=optitrop-lung04-nct05870319"},"offer":{"cited_clinicians":16,"cited_commentary_sources":36,"verified_hcp_statements":125,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":24},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"optitrop-lung04-nct05870319"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=optitrop-lung04-nct05870319","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/optitrop-lung04-nct05870319","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 125 verified statements · 52 from 16 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-20T00:39:35.003370Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":14,"no_commentary_found":0},"aspects":[{"claim_count":15,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":14,"title":"Primary endpoint: Progression-free survival (PFS)"},{"claim_count":19,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":16,"title":"Secondary endpoints"},{"claim_count":15,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":7,"title":"Population and setting"},{"claim_count":20,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":12,"title":"The comparison"},{"claim_count":18,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.interventions","source_count":13,"title":"Safety and tolerability"},{"claim_count":16,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":9,"title":"Design and conduct"},{"claim_count":17,"coverage":"discussed","id":"A1","source_count":13,"title":"Practice-change thresholds and platinum deferral"},{"claim_count":14,"coverage":"discussed","id":"A2","source_count":11,"title":"Geographic applicability, regulatory translation and access"},{"claim_count":7,"coverage":"discussed","id":"A3","source_count":6,"title":"Intracranial activity and patient-relevant outcomes"},{"claim_count":13,"coverage":"discussed","id":"A4","source_count":6,"title":"Resistance work-up and treatment sequencing"},{"claim_count":9,"coverage":"discussed","id":"A5","source_count":7,"title":"Biological rationale and ADC differentiation"},{"claim_count":11,"coverage":"discussed","id":"A6","source_count":8,"title":"Earlier-study context and uncertain study descriptions"},{"claim_count":9,"coverage":"discussed","id":"A7","source_count":8,"title":"Future combinations and earlier-line development"},{"claim_count":17,"coverage":"discussed","id":"A8","source_count":11,"title":"Analysis maturity, subsequent therapy and statistical interpretation"}],"counts":{"beyond_population_findings":3,"beyond_population_statements":12,"cited_clinicians":16,"cited_clinicians_by_role":{"physician":1,"physician, Medical oncology":15},"cited_physicians":16,"cited_sources":38,"claims_by_expression_type":{"comparison":11,"experience":2,"interpretation":33,"opinion":30,"primary_context":4,"question":4,"restatement":22,"uncertainty":8,"unspecified":11},"claims_by_kind":{"objective_result":2,"protocol_statement":2,"source_observation":121},"clinician_statements":52,"evidence_units":63,"findings":11,"organisational_accounts":2,"people_cited":28,"people_identity_verified":24,"people_total":28,"screened_sources":71,"verified_claims":125},"findings_index":[{"cited_clinicians":6,"id":"F1","structure":{"claims":16,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":16},"limitations":3,"links":{"context":1,"support":16},"ma_question":true,"named_voices":9,"passages":15,"sources":11,"sources_by_kind":{"commentary":7,"media":4}},"title":"Uptake: what speakers say","evidence_line":"16 statements from 9 speakers in 11 sources, 4 of them podcasts or videos"},{"cited_clinicians":5,"id":"F2","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":1,"views":9},"limitations":4,"links":{"context":1,"support":16},"ma_question":true,"named_voices":8,"passages":10,"sources":10,"sources_by_kind":{"commentary":8,"media":2}},"title":"China-only evidence: where speakers split on requiring global confirmation","title_holders":{"cited_claim_ids":["claim-5cb4ea41d431e86a6ed2","claim-e75f9744efbefc23bad0","claim-2b4041595eb1a2d1b6f8","claim-046a3745e852071f5289","claim-9c4eec98d07ce139f0d3","claim-66885e2e4f1a6baebee6","claim-3374f7ee63c7a4d86467","claim-6e7a93feebba0dc0b1ae"],"clinicians":false,"holders":6,"sides":[{"cited_claim_ids":["claim-5cb4ea41d431e86a6ed2","claim-e75f9744efbefc23bad0","claim-2b4041595eb1a2d1b6f8","claim-046a3745e852071f5289","claim-9c4eec98d07ce139f0d3","claim-66885e2e4f1a6baebee6","claim-3374f7ee63c7a4d86467"],"holders":5},{"cited_claim_ids":["claim-6e7a93feebba0dc0b1ae"],"holders":1}],"speakers":8,"view":"split"},"evidence_line":"13 statements from 8 speakers in 10 sources, 2 of them podcasts or videos","holder_line":"6 of the 8 named speakers in this finding take a side on this question: 5 on one side, 1 on the other"},{"cited_clinicians":5,"id":"F3","structure":{"claims":19,"claims_by_group":{"comparisons":3,"experience":0,"questions":0,"restated":8,"views":8},"limitations":5,"links":{"context":2,"support":20},"ma_question":true,"named_voices":10,"passages":17,"sources":14,"sources_by_kind":{"commentary":9,"media":4,"publication":1}},"title":"Grade ≥3: what speakers say","evidence_line":"19 statements from 10 speakers in 14 sources, 4 of them podcasts or videos"},{"cited_clinicians":5,"id":"F4","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":0,"views":4},"limitations":3,"links":{"context":0,"support":7},"ma_question":true,"named_voices":5,"passages":7,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"CNS activity: why most clinicians seek more evidence on brain metastases","title_holders":{"cited_claim_ids":["claim-7ec5da9e748ccfac0fed","claim-671eb178dec6779b4d2e","claim-c7e0d9050d66d2f00608","claim-fa7290f072b2c3294c15","claim-4f2b4d18cf795bec4095","claim-9e784f2de038ab4f389c"],"clinicians":true,"holders":4,"speakers":5,"view":"reading"},"evidence_line":"7 statements from 5 speakers in 6 sources, 1 of them a podcast or video","holder_line":"4 of the 5 named speakers in this finding hold this view, each a confirmed clinician"},{"cited_clinicians":9,"id":"F5","structure":{"claims":25,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":12,"views":11},"limitations":3,"links":{"context":3,"support":29},"ma_question":true,"named_voices":14,"passages":23,"sources":18,"sources_by_kind":{"commentary":15,"media":2,"publication":1}},"title":"OS benefit: most speakers highlight its size; a clinician notes a nominal p value","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-2117c2b2d6e999470ff0"],"clause":"a clinician notes a nominal p value","holders":1},"cited_claim_ids":["claim-f24acb04e3d1e6df82ad","claim-d99910863d6dff55ddae","claim-4ac8fc4e67e28f3c35c2","claim-fc07b17d26d6bf3d65b8","claim-e0c1efef8a7677383d65","claim-18a9ff74f69f24d53ee1","claim-9faa6503a5773fd8c621","claim-2b4041595eb1a2d1b6f8","claim-d9632ae576d32eabd705","claim-42f6a82b96c2738b1a8c","claim-7091266da3cdc0822b3b","claim-d63751c121a62ac8b10c","claim-cee72f2778d10845d085","claim-4e0f55aeebef5de58ef5","claim-65e474d6cde5ef874c8e","claim-10958177e61c23cdbabd-3f513f6e"],"clinicians":false,"holders":12,"speakers":14,"view":"reading"},"evidence_line":"25 statements from 14 speakers in 18 sources, 2 of them podcasts or videos","holder_line":"12 of the 14 named speakers in this finding hold this view; 1 of the 14 holds its caveat, “a clinician notes a nominal p value”"},{"cited_clinicians":4,"id":"F6","structure":{"claims":20,"claims_by_group":{"comparisons":5,"experience":0,"questions":2,"restated":6,"views":7},"limitations":5,"links":{"context":1,"support":22},"ma_question":true,"named_voices":7,"passages":14,"sources":12,"sources_by_kind":{"commentary":7,"media":4,"publication":1}},"title":"Post-EGFR-TKI: most speakers weigh options but a clinician cannot yet rank them","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-c98362e8d4ecb2a21dee"],"clause":"a clinician cannot yet rank them","holders":1},"cited_claim_ids":["claim-b50fabd5f97e8de60f49","claim-82aefbdc2381bb70cc16","claim-f088fe93c976bb34ea02","claim-bb6e3453fd577b38c27a","claim-ed0b5d1c508aaac79d63","claim-cde5e6ff3edab70f8f48","claim-fa7290f072b2c3294c15","claim-c98362e8d4ecb2a21dee","claim-f142bf1759127e15dea9","claim-5ac0e6701a8179de63ec","claim-13db78437ee4e033c93b","claim-43da149feeb5c9bf1132","claim-3ff148f1f72c425fdf82"],"clinicians":false,"holders":5,"speakers":7,"view":"reading"},"evidence_line":"20 statements from 7 speakers in 12 sources, 4 of them podcasts or videos","holder_line":"5 of the 7 named speakers in this finding hold this view; 1 of them holds its caveat, “a clinician cannot yet rank them”"},{"cited_clinicians":2,"id":"F7","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":1,"questions":2,"restated":3,"views":5},"limitations":4,"links":{"context":0,"support":12},"ma_question":true,"named_voices":3,"passages":7,"sources":4,"sources_by_kind":{"commentary":2,"media":1,"publication":1}},"title":"Post-EGFR-TKI choices: why speakers want testing and biomarkers to guide therapy","title_holders":{"cited_claim_ids":["claim-f55cf6a777593e91492d","claim-5bdfbc2e56fd58b5c588","claim-e2f3f1b20d63614e9a68"],"clinicians":false,"holders":3,"speakers":3,"view":"reading"},"evidence_line":"11 statements from 3 speakers in 4 sources, 1 of them a podcast or video","holder_line":"3 of the 3 named speakers in this finding hold this view"},{"cited_clinicians":3,"id":"F8","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":2,"views":6},"limitations":3,"links":{"context":1,"support":9},"ma_question":true,"named_voices":7,"passages":8,"sources":7,"sources_by_kind":{"commentary":4,"media":3}},"title":"TROP2 ADCs: where speakers split on class-wide versus drug-specific implications","title_holders":{"cited_claim_ids":["claim-ad53ff86258e7431e7c6","claim-671eb178dec6779b4d2e","claim-fac678d140b2cc53ab69","claim-676daca0fdf3525cb911","claim-a3b7985d6da52eb31e6d","claim-496b76ad62d9c4e38962"],"clinicians":false,"holders":5,"sides":[{"cited_claim_ids":["claim-ad53ff86258e7431e7c6","claim-671eb178dec6779b4d2e","claim-fac678d140b2cc53ab69","claim-676daca0fdf3525cb911"],"holders":3},{"cited_claim_ids":["claim-a3b7985d6da52eb31e6d","claim-496b76ad62d9c4e38962"],"holders":2}],"speakers":7,"view":"split"},"evidence_line":"9 statements from 7 speakers in 7 sources, 3 of them podcasts or videos","holder_line":"5 of the 7 named speakers in this finding take a side on this question: 3 on one side, 2 on the other"},{"cited_clinicians":3,"id":"F9","population":"beyond","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":1,"views":6},"limitations":4,"links":{"context":0,"support":10},"ma_question":true,"named_voices":6,"passages":9,"sources":7,"sources_by_kind":{"commentary":4,"media":3}},"title":"ADC R&D: what speakers say","evidence_line":"8 statements from 6 speakers in 7 sources, 3 of them podcasts or videos"},{"cited_clinicians":1,"id":"F10","population":"beyond","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":4,"views":5},"limitations":4,"links":{"context":0,"support":9},"ma_question":true,"named_voices":3,"passages":6,"sources":6,"sources_by_kind":{"commentary":4,"media":2}},"title":"Prior ADC work: most speakers note activity signals; most see care changing","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-56a17a278b07db802fa4","claim-13311d88cfcb485a1188"],"clause":"most see care changing","holders":2},"cited_claim_ids":["claim-0c2f2e17413dbc7ea5ec","claim-56a17a278b07db802fa4","claim-f520ecbcd64b91666874","claim-c17227141fc2a0960ae8","claim-32b0cf36f2fadd7b505c","claim-00c2a1fb620a65783f1d"],"clinicians":false,"holders":2,"speakers":3,"view":"reading"},"evidence_line":"9 statements from 3 speakers in 6 sources, 2 of them podcasts or videos","holder_line":"2 of the 3 named speakers in this finding hold this view; 2 of the 3 hold its caveat, “most see care changing”"},{"cited_clinicians":0,"id":"F_C116_cross_population_context","population":"beyond","structure":{"claims":1,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":0},"limitations":1,"links":{"context":0,"support":1},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"From EGFR-mutant to PD-L1-negative NSCLC: how a speaker sees an ADC shift","title_holders":{"cited_claim_ids":["claim-13311d88cfcb485a1188"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"1 statement from 1 speaker in 1 source","holder_line":"The one named speaker in this finding holds this view"}],"open_question":{"basis":"From findings F1 (16 statements from 9 speakers in 11 sources) and F2 (13 statements from 8 speakers in 10 sources)","cited_claim_ids":["claim-e4c04473052727b6f18f","claim-82aefbdc2381bb70cc16","claim-66885e2e4f1a6baebee6","claim-0c47a6adc43ec2063d50","claim-4f2b4d18cf795bec4095","claim-230ee2320e2a7089a842","claim-6e7a93feebba0dc0b1ae","claim-5cb4ea41d431e86a6ed2","claim-e75f9744efbefc23bad0","claim-2b4041595eb1a2d1b6f8","claim-046a3745e852071f5289","claim-4a5a4c75bb7ea973a6ae","claim-9c4eec98d07ce139f0d3","claim-fa7290f072b2c3294c15","claim-3374f7ee63c7a4d86467","claim-f22e4374b29ca546340e"],"finding_ids":["F1","F2"],"question":"Where sacituzumab tirumotecan is available outside China, is global confirmation of OptiTROP-Lung04 needed before using it to defer platinum chemotherapy after EGFR-TKI progression in advanced EGFR-mutant NSCLC?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Speakers welcome a possible way to defer platinum, but differ on when sac-TMT should change practice"},{"id":"section-2","level":2,"title":"Accounts seek global applicability evidence; one questions unequal confirmation standards"},{"id":"section-3","level":2,"title":"How do speakers weigh favorable tolerability impressions against neutropenia, stomatitis and lower-grade burden?"},{"id":"section-4","level":2,"title":"Speakers ask whether systemic benefit is matched by intracranial activity"},{"id":"section-5","level":2,"title":"Speakers read the survival evidence favorably, with qualifications about analysis maturity and subsequent treatment"},{"id":"section-6","level":2,"title":"Speakers weigh alternatives to sac-TMT; one X account says the preferred option remains unresolved"},{"id":"section-7","level":2,"title":"Accounts want molecular work-up to preserve targeted options when weighing an ADC"},{"id":"section-8","level":2,"title":"Speakers see a new targeting strategy, while one account warns against treating TROP2 ADCs as interchangeable"},{"id":"section-9","level":2,"title":"Beyond the trial population"},{"id":"section-10","level":3,"title":"Speakers see sequencing and combination research expanding options; one episode questions a first-line EGFR move"},{"id":"section-11","level":3,"title":"Accounts and a video welcome earlier sac-TMT work in EGFR-resistant disease"},{"id":"section-12","level":3,"title":"One LinkedIn account sees an ADC treatment shift across EGFR-mutant and PD-L1-negative NSCLC"},{"id":"section-13","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":3},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":9}],"id":"T1","label":"Primary endpoint: Progression-free survival (PFS)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":16}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":2},{"id":"F7","shared_claims":4},{"id":"F8","shared_claims":2}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":19},{"id":"F7","shared_claims":2},{"id":"F8","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F3","shared_claims":16},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":9},{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":5},{"id":"F7","shared_claims":2}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-20T00:39:35.003370Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-20T00:55:36Z","record_hash":"d5bc421ae0a1f79bcc105194a3d8b557f36927c36c58293a4810a3561fd997dd","release_hash":"9d960d780150a19405aa25d85f2ca1c6ebb6322b4aaea7c51101c751699811a5","report_id":"erudio-nct05870319","run_id":"bf4412cf-0076-44e9-9592-496833960d4b","schema_version":"5.0","slug":"optitrop-lung04-nct05870319","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"The clinicians cited read OptiTROP-Lung04 as supporting an active option that could move platinum later in treatment, but differ on readiness to use sac-TMT. One medical oncologist supports treatment change where it is available; another anticipates future rather than immediate change. A speaker would move toward sac-TMT only with access and global replication. Clinicians still seek CNS data, while final survival estimates are described through commentary rather than a separate final-results publication.","examples":[],"meta_description":"71 sources screened · 125 verified statements (52 from clinicians verified by NPI or staff page) from 38 sources · 11 findings. Updated Nov 20, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-20T00:55:36Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":71},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","1 matching source (1 X thread) could not be read and is not included.","Not yet captured in this edition: a view on alternative antibody–drug conjugates’ benefit–risk, evidence maturity and geographic applicability after EGFR-TKI failure; a view on alternative ADC efficacy, toxicity, dose modification and supportive-care needs after EGFR-TKI failure.","57 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 64 sources about other trials or topics are not included.","The sources reviewed for this edition are not a representative sample of HCPs. Repeated posts and presentation summaries do not establish independent agreement.","Public discussion that did not use recognizable trial names or wording may be absent. One potentially relevant X discussion could not be read.","Several recorded passages cannot be attributed to a named speaker. They remain attached to their discussion or episode and cannot establish additional independent participants.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The linked publication reports final PFS and preplanned interim OS. Final OS estimates in this report come from commentary about the 2026 update, not a separate final-results publication.","Some sources differ on the comparator, treatment history, endpoint hierarchy, safety measure or study name. Their descriptions remain attributed commentary rather than a single reconciled result.","No full protocol was available in the sources reviewed, and the regulatory material does not establish an exact label for SKB264. The report therefore does not determine regulatory status or resolve protocol-level questions.","Earlier or unidentified sac-TMT studies provide contextual material, not evidence for Lung04's own platinum-comparator result.","Descriptions of alternative-regimen and access discussions are incomplete. SAFFRON is represented here by biomarker-selection comments rather than a full quantitative benefit–risk assessment, and not every speaker's assessment of the other ADCs is available. The report therefore cannot provide an exhaustive account of reasons to choose or withhold each alternative."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":3,"linkedin_post":11,"other":0,"podcast":1,"publication":1,"registry":1,"regulatory":0,"x_thread":15,"x_video":0,"youtube":6},"by_evidence_role":{"commentary":36,"methods":1,"results":1},"count":38,"evidence_window":{"end":"2026-11-13","start":"2025-06-01"},"retrieval_snapshot":"2026-11-19T23:38:41.595466Z","timeline":[{"count":2,"week":"2025-W22"},{"count":1,"week":"2025-W35"},{"count":2,"week":"2025-W40"},{"count":7,"week":"2025-W42"},{"count":4,"week":"2025-W43"},{"count":1,"week":"2025-W44"},{"count":1,"week":"2025-W46"},{"count":1,"week":"2025-W47"},{"count":1,"week":"2025-W48"},{"count":1,"week":"2025-W49"},{"count":1,"week":"2026-W01"},{"count":1,"week":"2026-W04"},{"count":1,"week":"2026-W05"},{"count":1,"week":"2026-W38"},{"count":8,"week":"2026-W43"},{"count":2,"week":"2026-W44"},{"count":1,"week":"2026-W46"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT05870319:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05870319:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:41124220","quote_policy":"short_quote_link_out"},{"id":"openfda:fa8f1f52-3f05-4ae8-bfec-7f0a029e6825:20260921","quote_policy":"short_quote_link_out"},{"id":"openfda:f91c48da-68d1-4aa7-89b8-d84a3e8b629b:20261109","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-4w7jzkpdswrg7tf4azxu3gsc-3m3luh3snod2q","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-4ysesz2mn5ig5vitaq3qdjos-3m4dwuamrgl26","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-7eeegxgy3hkpipqnlzr7na4c-3m3lq6bcynz2y","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-7eeegxgy3hkpipqnlzr7na4c-3m3mha53sdn2v","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-cg5bjyxf74w3vg7lo4zqwpzg-3m3klrjjmc62c","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-hslirr7h6d7livppaxty435b-3m3lqklr52w2w","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-hslirr7h6d7livppaxty435b-3m3mhzbuinq2i","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-jf26a7dgps3fck4zc7anchdl-3m5vu5rsxc32j","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-jf26a7dgps3fck4zc7anchdl-3m5vu5sirmb2d","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-mgwrki6irihfcatu2v347soc-3m3kjnc55kb2c","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-mgwrki6irihfcatu2v347soc-3mbelyhy4rc2o","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-vvvhpax6mtymhk7n3qiv36af-3m3jlxsnpoc2e","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-vvvhpax6mtymhk7n3qiv36af-3m3kla7qba226","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-vvvhpax6mtymhk7n3qiv36af-3m3krmdeitc26","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-yk5mvwzdjpy45i4ph7at4xmx-3myp4adrtq22w","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ypu6bwefbbzhcvojdj7mz657-3mzsjlafx6726","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3m3evwf5jos2y","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3m3knposfjq2e","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7378610671581564928","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7378789078911315968","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7385696504637800448","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7385928874565742593","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7386294174959988736","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7423432747412537344","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7505951208755535872","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7518630094341582849","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7520067516971352064","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7520165856216211456","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7520387843924434944","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:1fa766","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1683826199921844224:296a1735-1d4d-4920-bcd8-a89de542b7bb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929196843025527172:6a2c15b2-2a25-4fdd-99f5-006272703b73","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929198335388164397:6e5451f5-f0b0-468b-bbca-a9ec31367625","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1974104651210580245:cfee4c5c-dcae-48d0-96b5-5e5a3211ff8b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1977053351155318878:ab58f310-9894-42f2-bb5d-c5a70fe397aa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979926136017895601:74cbb5ec-0da5-4b31-8202-15b8880b9a33","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979926401374396465:a7e4b36c-56d1-4f76-a083-bac3a299d8f5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979928483422711839:668ae32b-1b9d-4526-a9b2-8d2c9835c806","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979929544870998384:7cd0fc7f-8fff-4f75-9b90-0b6bd0bb66ce","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979930224931307529:40b89fd3-fcd6-4617-8515-24bd6dfaa663","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979931138773618938:6f3f41ae-bc01-4354-b0ac-09be76377733","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979934003160547682:c8d470ac-f490-4f23-803b-fd0f4b0900bb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979943930616517034:f6f78010-f7d1-4f2a-8384-9c8162a48ef2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979952632879005911:1469e812-8129-4fe5-9742-16a997417257","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979979811457249343:149839c1-71fd-4825-9b00-874dbb0ebd0e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980160447522492510:1e2e9bd2-5a3c-46ae-8299-6e6863d847a2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1983097364710863162:225bf3a9-d5ad-4c00-8593-01e910f5a936","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2007186320570093849:2f82ecbd-936b-43fa-b4f5-2b2d07fbfaa3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060508634614800601:7a1fead5-8495-40c0-8f95-64ae9def55f8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102759899302367581:4912d6d5-d21a-400a-b4b9-6fc4a5dcfad3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112906577472627072:d69cdca9-104a-41ba-831d-69825db755e4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112906692107149421:0d47b921-5fea-4cc7-a1df-db8dc4b7e267","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112911160416633189:db4ea10c-75d2-4ee8-aca1-b807937f8d81","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114206604057047084:ff5d2770-a88d-46a3-983a-85c1a413e189","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114299639700525221:d603a2a0-d7f3-4d7c-81e2-aa8621a2969d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114299828905886198:ff9efc62-b59e-4500-9908-40652f820dae","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114300074234921268:bab1accc-b7c1-4267-b166-a063fceb4762","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114300095579689008:64702dec-a765-4619-bd08-80403d241038","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114300463881281573:b1c5c6eb-e401-4708-92fa-acfb3ce70bd6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114300506512486578:7f3b5669-7213-4fbc-8ecb-120f7407285e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114301182982180924:21264e85-3d0b-4100-b50a-2c8d28520bb4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114838033493016642:749533dd-ff73-42b0-a7fe-03adf86688db","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115806236025270442:b5a76d76-3479-48a1-9d62-b4806e2c11d2","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:2hez_efX3IE","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:6SJiy-xt3d8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:9qeSxkaVW3g","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:9yAVMXwRbVk","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:L_OoTt0n80w","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:aLwiXf6sMh0","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:fdQ-4n27RHE","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:gJn5RA_SIwI","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":18,"linkedin_post":11,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":33,"x_video":0,"youtube":8},"by_evidence_role":{"commentary":71},"count":71,"evidence_window":{"end":"2026-11-13","start":"2023-07-25"},"retrieval_snapshot":"2026-11-19T23:38:42.019923Z","timeline":[{"count":1,"week":"2023-W30"},{"count":2,"week":"2025-W22"},{"count":1,"week":"2025-W35"},{"count":3,"week":"2025-W40"},{"count":1,"week":"2025-W41"},{"count":18,"week":"2025-W42"},{"count":8,"week":"2025-W43"},{"count":2,"week":"2025-W44"},{"count":1,"week":"2025-W46"},{"count":3,"week":"2025-W47"},{"count":1,"week":"2025-W48"},{"count":1,"week":"2025-W49"},{"count":1,"week":"2025-W50"},{"count":2,"week":"2026-W01"},{"count":1,"week":"2026-W04"},{"count":1,"week":"2026-W05"},{"count":1,"week":"2026-W15"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W38"},{"count":1,"week":"2026-W39"},{"count":15,"week":"2026-W43"},{"count":3,"week":"2026-W44"},{"count":1,"week":"2026-W45"},{"count":1,"week":"2026-W46"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":5,"linkedin_post":34,"other":0,"podcast":10,"publication":3,"registry":1,"regulatory":0,"x_thread":34,"x_video":0,"youtube":38}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":[{"label":"ESMO Congress 2026","slug":"esmo26","sources":6}],"drugs":[{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"sacituzumab tirumotecan","slug":"sacituzumab-tirumotecan"},{"brand_names":["Alimta"],"label":"pemetrexed","slug":"pemetrexed"},{"brand_names":["Paraplatin"],"label":"carboplatin","slug":"carboplatin"},{"brand_names":["Platinol"],"label":"cisplatin","slug":"cisplatin"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"OptiTROP-Lung04","aliases":["OptiTROP-Lung04","SKB264-Ⅲ-09","A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients","A Randomized, Open-Label, Multicenter Phase 3 Study to Evaluate SKB264 Monotherapy Versus Pemetrexed in Combination With Platinum in Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutation Who Have Failed to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Therapy"],"brief_title":"A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non-small Cell Lung Cancer"],"display_condition":"EGFR-TKI-resistant, EGFR-mutated advanced NSCLC","display_interventions":[["sacituzumab tirumotecan (SKB264)"]],"enrollment":{"count":376,"type":"ACTUAL"},"interventions":[{"name":"SKB264","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Pemetrexed","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Carboplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Cisplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT05870319","official_title":"A Randomized, Open-Label, Multicenter Phase 3 Study to Evaluate SKB264 Monotherapy Versus Pemetrexed in Combination With Platinum in Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutation Who Have Failed to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Therapy","other_names":[{"kind":"also","name":"OptiTROP-4"}],"overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2024-07-11","type":"ACTUAL"},"primary_endpoints":[{"description":"PFS assessed by BIRC per RECIST 1.1","measure":"Progression-free survival (PFS)","timeFrame":"From baseline until disease progression, death, or other protocol defined reason,up to approximately 36 months"}],"registered_date":{"date":"2023-05-23","type":"ACTUAL"},"registry_last_updated":"2026-05-08","registry_url":"https://clinicaltrials.gov/study/NCT05870319","short_name":"OptiTROP-Lung04","short_name_basis":"canonical_name","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","start_date":{"date":"2023-06-26","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"SKB264-Ⅲ-09","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}